Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages

Bicyclic oxazaphospholidine monomers were used to prepare a series of phosphorothioate (PS)-modified gapmer antisense oligonucleotides (ASOs) with control of the chirality of each of the PS linkages within the 10-base gap. The stereoselectivity was determined to be 98% for each coupling. The objective of this work was to study how PS chirality influences biophysical and biological properties of the ASO including binding affinity (Tm), nuclease stability, activity in vitro and in vivo, RNase H activation and cleavage patterns (both human and E. coli) in a gapmer context. Compounds that had nine or more Sp-linkages in the gap were found to be poorly active in vitro, while compounds with uniform Rp-gaps exhibited activity very similar to that of the stereo-random parent ASOs. Conversely, when tested in vivo, the full Rp-gap compound was found to be quickly metabolized resulting in low activity. A total of 31 ASOs were prepared with control of the PS chirally of each linkage within the gap in an attempt to identify favorable Rp/Sp positions. We conclude that a mix of Rp and Sp is required to achieve a balance between good activity and nuclease stability.

[1]  H. Vosberg,et al.  Effect of deoxynucleoside phosphorothioates incorporated in DNA on cleavage by restriction enzymes. , 1982, The Journal of biological chemistry.

[2]  A. Levin,et al.  Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. , 2001, Current opinion in investigational drugs.

[3]  S. Crooke,et al.  Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. , 2001, Biochemical pharmacology.

[4]  M. Manoharan,et al.  Lipid nanoparticles improve activity of single-stranded siRNA and gapmer antisense oligonucleotides in animals. , 2013, ACS chemical biology.

[5]  W. Stec,et al.  Stereodependent inhibition of plasminogen activator inhibitor type 1 by phosphorothioate oligonucleotides: proof of sequence specificity in cell culture and in vivo rat experiments. , 1997, Antisense & nucleic acid drug development.

[6]  E. Swayze,et al.  The Medicinal Chemistry of Oligonucleotides , 2008 .

[7]  D. Witchell,et al.  Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. , 2009, Journal of medicinal chemistry.

[8]  R. Ghirlando,et al.  Specific recognition of RNA/DNA hybrid and enhancement of human RNase H1 activity by HBD , 2008, The EMBO journal.

[9]  T. P. Prakash,et al.  Synthesis and biophysical evaluation of 2',4'-constrained 2'O-methoxyethyl and 2',4'-constrained 2'O-ethyl nucleic acid analogues. , 2010, The Journal of organic chemistry.

[10]  P. Linsley,et al.  Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 ‘Slicer’ independent and can be mediated by Ago1 , 2009, Nucleic acids research.

[11]  T. Wada,et al.  Stereocontrolled synthesis of oligonucleotide analogs containing chiral internucleotidic phosphorus atoms. , 2011, Chemical Society reviews.

[12]  Robert H. Brown,et al.  Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. , 2014, Cell reports.

[13]  C. Leumann,et al.  Screening the structural space of bicyclo-DNA: Synthesis and thermal melting properties of bc4,3-DNA , 2009 .

[14]  W. Stec,et al.  Stereodifferentiation--the effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of bacterial RNase H. , 1995, Nucleic acids research.

[15]  Wei Yang,et al.  Crystal Structures of RNase H Bound to an RNA/DNA Hybrid: Substrate Specificity and Metal-Dependent Catalysis , 2005, Cell.

[16]  D. Vassylyev,et al.  DNA-repair enzymes. , 1993, Current opinion in structural biology.

[17]  K. Fearon,et al.  Phosphorothioate oligodeoxynucleotides: large-scale synthesis and analysis, impurity characterization, and the effects of phosphorus stereochemistry. , 1997, Ciba Foundation symposium.

[18]  A. Katritzky,et al.  (Trifluoroacetyl)benzotriazole: A Convenient Trifluoroacetylating Reagent. , 1997, The Journal of organic chemistry.

[19]  D. Friend,et al.  HIGH-YIELD PREPARATION OF ISOLATED RAT LIVER PARENCHYMAL CELLS , 1969, The Journal of cell biology.

[20]  H. Almer,et al.  Synthesis of diribonucleoside phosphorothioates via stereospecific sulfuration of H-phosphonate diesters , 1992 .

[21]  F. Eckstein,et al.  Inhibition of deoxyribonucleases by phosphorothioate groups in oligodeoxyribonucleotides. , 1988, Nucleic acids research.

[22]  S. Crooke,et al.  Human RNase H1 Discriminates between Subtle Variations in the Structure of the Heteroduplex Substrate , 2007, Molecular Pharmacology.

[23]  Helen H. Hobbs,et al.  Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.

[24]  Shuling Guo,et al.  Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. , 2014, Cell reports.

[25]  S. Crooke,et al.  Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs* , 2004, Journal of Biological Chemistry.

[26]  F. Eckstein.  Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? , 2000, Antisense & nucleic acid drug development.

[27]  S. Crooke,et al.  The Positional Influence of the Helical Geometry of the Heteroduplex Substrate on Human RNase H1 Catalysis , 2007, Molecular Pharmacology.

[28]  P. D. Cook,et al.  Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA , 1999, Nature Structural Biology.

[29]  C. Bennett,et al.  RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. , 2010, Annual review of pharmacology and toxicology.

[30]  David R Corey,et al.  RNA interference in mammalian cells by chemically-modified RNA. , 2003, Biochemistry.

[31]  M. Lindholm,et al.  Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates , 2010, Nucleic acids research.

[32]  R. Crouch,et al.  Ribonuclease H: the enzymes in eukaryotes , 2009, The FEBS journal.

[33]  S. Crooke.  Antisense Drug Technology , 2001 .

[34]  Stanley T Crooke,et al.  Human RNase H1 Uses One Tryptophan and Two Lysines to Position the Enzyme at the 3′-DNA/5′-RNA Terminus of the Heteroduplex Substrate* , 2003, Journal of Biological Chemistry.

[35]  S. Crooke,et al.  Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B , 2013, British journal of clinical pharmacology.

[36]  K. Stecker,et al.  In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. , 1998, The Journal of pharmacology and experimental therapeutics.

[37]  B. Monia,et al.  Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals , 2006, Nucleic acids research.

[38]  S. Agrawal,et al.  Enzymatic Synthesis of Stereoregular (All Rp) Oligonucleotide Phosphorothioate and Its Properties , 1995 .

[39]  M. Egli,et al.  Synthesis, improved antisense activity and structural rationale for the divergent RNA affinities of 3'-fluoro hexitol nucleic acid (FHNA and Ara-FHNA) modified oligonucleotides. , 2011, Journal of the American Chemical Society.

[40]  S. Crooke,et al.  Structural Requirements at the Catalytic Site of the Heteroduplex Substrate for Human RNase H1 Catalysis* , 2004, Journal of Biological Chemistry.

[41]  J. Kastelein,et al.  Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B , 2006, Circulation.

[42]  Stanley T. Crooke,et al.  Single-Stranded siRNAs Activate RNAi in Animals , 2012, Cell.

[43]  T. Wada,et al.  An oxazaphospholidine approach for the stereocontrolled synthesis of oligonucleoside phosphorothioates. , 2003, Journal of the American Chemical Society.

[44]  D. L. Cole,et al.  Influence of Diastereomeric Ratios of Deoxyribonucleoside Phosphoramidites on the Synthesis of Phosphorothioate Oligonucleotides , 2000, Nucleosides, nucleotides & nucleic acids.

[45]  W. Stec,et al.  Diastereomers of Nucleoside 3'-O-(2-Thio-1,3,2-oxathia(selena)phospholanes): Building Blocks for Stereocontrolled Synthesis of Oligo(nucleoside phosphorothioate)s , 1995 .

[46]  W. Stec,et al.  Stability of stereoregular oligo(nucleoside phosphorothioate)s in human plasma: diastereoselectivity of plasma 3'-exonuclease. , 1997, Antisense & nucleic acid drug development.

[47]  Hui-Ling Chen,et al.  Porcine Spleen Deoxyribonuclease II , 1998, The Journal of Biological Chemistry.

[48]  T. Wada,et al.  Solid-phase synthesis of stereoregular oligodeoxyribonucleoside phosphorothioates using bicyclic oxazaphospholidine derivatives as monomer units. , 2008, Journal of the American Chemical Society.

[49]  Dong Yu,et al.  Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological properties. , 2000, Bioorganic & medicinal chemistry.

[50]  W. Stec,et al.  Stereocontrolled Synthesis of Oligo(nucleoside phosphorothioate)s , 1994 .

[51]  D. Ittig,et al.  TricycloDNA-modified oligo-2′-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues—a comparative study of oligonucleotide length, design and chemistry , 2012, Nucleic acids research.

[52]  P. Frey,et al.  Bond order and charge localization in nucleoside phosphorothioates. , 1985, Science.

[53]  C. Echeverri,et al.  Host scavenger receptor SR-BI plays a dual role in the establishment of malaria parasite liver infection. , 2008, Cell host & microbe.

[54]  W. Stec,et al.  Oxathiaphospholane Method of Stereocontrolled Synthesis of Diribonucleoside 3',5'-Phosphorothioates. , 1996, The Journal of organic chemistry.